Published in Acta Oncol on June 01, 2011
Impact of Exercise on Prognostic Biomarkers Related to Prostate Cancer | NCT03397030
Retracted Association of Polymorphism rs198977 in Human Kallikrein-2 Gene (KLK2) with Susceptibility of Prostate Cancer: A Meta-Analysis. PLoS One (2013) 1.37
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther (2015) 1.33
Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One (2012) 1.23
MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214. PLoS One (2013) 1.19
Current status of biomarkers for prostate cancer. Int J Mol Sci (2013) 1.17
Risk stratification in prostate cancer screening. Nat Rev Urol (2012) 1.13
High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression. Diagn Pathol (2011) 1.00
A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells. Prostate Cancer Prostatic Dis (2013) 0.95
BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer. PLoS One (2013) 0.90
Novel tools for prostate cancer prognosis, diagnosis, and follow-up. Biomed Res Int (2014) 0.89
Imaging active urokinase plasminogen activator in prostate cancer. Cancer Res (2015) 0.88
Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics. PLoS One (2012) 0.88
First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts. Nucl Med Biol (2013) 0.87
Oxidative stress measured by thioredoxin reductase level as potential biomarker for prostate cancer. Am J Cancer Res (2015) 0.87
Circulating MicroRNA as Biomarkers: An Update in Prostate Cancer. Mol Cell Pharmacol (2011) 0.86
Clinical features and prognostic factors for patients with bone metastases from prostate cancer. Asian J Androl (2012) 0.86
The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used? World J Urol (2014) 0.83
Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes. Theranostics (2016) 0.82
Circulatory miR-628-5p is downregulated in prostate cancer patients. Tumour Biol (2014) 0.82
Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer. Mol Cell Proteomics (2014) 0.82
Amplification and protein expression of androgen receptor gene in prostate cancer cells: Fluorescence in situ hybridization analysis. Oncol Lett (2015) 0.81
Identification of plasma protein profiles associated with risk groups of prostate cancer patients. Proteomics Clin Appl (2014) 0.79
Evaluation of 12-lipoxygenase (12-LOX) and plasminogen activator inhibitor 1 (PAI-1) as prognostic markers in prostate cancer. Biomed Res Int (2014) 0.79
Patented prostate cancer biomarkers. Nat Rev Urol (2012) 0.79
Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer. Ther Adv Urol (2014) 0.78
Transperineal template prostate biopsies in men with raised PSA despite two previous sets of negative TRUS-guided prostate biopsies. World J Urol (2013) 0.78
Kallikreins as biomarkers for prostate cancer. Biomed Res Int (2014) 0.77
Future prospects in the diagnosis and management of localized prostate cancer. ScientificWorldJournal (2013) 0.77
Death receptor 5 expression is inversely correlated with prostate cancer progression. Mol Med Rep (2014) 0.76
Loss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer. Med Oncol (2015) 0.75
Isothiocyanate-Functionalized Bifunctional Chelates and fac-[M(I)(CO)3](+) (M = Re, (99m)Tc) Complexes for Targeting uPAR in Prostate Cancer. Bioconjug Chem (2015) 0.75
Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. BMC Cancer (2016) 0.75
TGF-β1 serum concentrations and receptor expressions in the lens capsular of dogs with diabetes mellitus. Open Vet J (2017) 0.75
KLK-targeted Therapies for Prostate Cancer. EJIFCC (2014) 0.75
Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. PLoS One (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making (2006) 11.83
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 8.60
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 6.40
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer (2008) 4.15
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol (2007) 3.72
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst (2006) 3.62
Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem (1992) 3.57
Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA (2005) 2.85
Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet (1994) 2.83
An updated catalog of prostate cancer predictive tools. Cancer (2008) 2.82
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak (2008) 2.64
The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol (2003) 2.59
Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst (2007) 2.49
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev (2001) 2.47
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology (2001) 2.38
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol (2006) 2.24
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol (2008) 2.20
Assessing individual risk for prostate cancer. J Clin Oncol (2007) 2.13
Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst (2003) 2.11
Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res (1998) 2.07
Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res (2000) 2.07
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol (2007) 2.06
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol (2009) 2.05
Development of common data elements: the experience of and recommendations from the early detection research network. Int J Med Inform (2003) 2.04
Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol (2007) 2.02
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol (2006) 1.99
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol (2007) 1.95
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res (2008) 1.90
Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem (2006) 1.88
Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol (2001) 1.86
Methods of calculating prostate-specific antigen velocity. Eur Urol (2006) 1.84
Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol (1994) 1.81
Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer (2004) 1.73
Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology (2001) 1.65
Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population. Urology (1996) 1.56
Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population. J Urol (2009) 1.55
Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol (2001) 1.55
Systematic review of statistical methods used in molecular marker studies in cancer. Cancer (2008) 1.53
Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology (2006) 1.51
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology (2003) 1.46
Free prostate-specific antigen in serum is becoming more complex. Urology (2002) 1.46
Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res (2004) 1.45
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology (2000) 1.44
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol (2004) 1.44
A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res (2001) 1.41
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol (2003) 1.40
Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer (2008) 1.39
Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate (2002) 1.30
Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res (2009) 1.26
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology (2004) 1.25
A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate (2009) 1.25
A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res (2010) 1.24
The association between total prostate specific antigen concentration and prostate specific antigen velocity. J Urol (2007) 1.24
Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol (2004) 1.20
Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem (2005) 1.20
Inventory of prostate cancer predictive tools. Curr Opin Urol (2008) 1.20
"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology (2000) 1.20
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol (2008) 1.18
Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? Urology (1999) 1.18
Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem (2010) 1.17
Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol (1997) 1.17
A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer (2010) 1.16
Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate (1999) 1.16
Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res (1992) 1.15
Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer (2001) 1.14
New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis (2007) 1.12
Challenges of cancer biomarker profiling. Eur Urol (2007) 1.10
Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology (2000) 1.10
Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer (2007) 1.09
Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer (2007) 1.09
Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med (1995) 1.09
Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol (1998) 1.09
Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology (1995) 1.08
Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol (2004) 1.07
Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol (2004) 1.07
The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int J Cancer (2007) 1.04
New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res (2003) 1.02
Intermethod differences in results for total PSA, free PSA, and percentage of free PSA. Am J Clin Pathol (2008) 1.02
Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate (2009) 1.02
Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol (2000) 1.00
Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol (2004) 0.99
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol (2008) 5.64
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol (2009) 5.62
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer (2008) 4.15
Empirical study of data sharing by authors publishing in PLoS journals. PLoS One (2009) 4.09
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol (2008) 4.02
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol (2007) 3.72
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. BMJ (2010) 3.38
Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol (2012) 3.12
Low annual caseloads of United States surgeons conducting radical prostatectomy. J Urol (2009) 3.04
Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97
ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol (2009) 2.91
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol (2008) 2.88
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med (2015) 2.71
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ (2014) 2.61
Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol (2008) 2.57
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. Trials (2010) 2.54
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol (2006) 2.50
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol (2007) 2.42
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
Complications after radical and partial nephrectomy as a function of age. J Urol (2010) 2.36
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol (2012) 2.27
PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer (2007) 2.27
Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated? J Clin Oncol (2010) 2.26
Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology (2007) 2.23
Surgical practice patterns for male urinary incontinence: analysis of case logs from certifying American urologists. J Urol (2012) 2.20
Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst (2014) 2.16
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc Natl Acad Sci U S A (2011) 2.14
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
A simple schema for informed decision making about prostate cancer screening. Ann Intern Med (2014) 2.12
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem (2005) 2.05
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol (2009) 2.05
Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care. BMJ (2004) 2.03
Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int (2006) 2.00
Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol (2004) 1.99
Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. Eur Urol (2006) 1.94
Variations among experienced surgeons in cancer control after open radical prostatectomy. J Urol (2010) 1.93
Lead time associated with screening for prostate cancer. Int J Cancer (2004) 1.93
Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol (2009) 1.91
Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int (2008) 1.88
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov (2012) 1.87
Decision curve analysis: a discussion. Med Decis Making (2008) 1.87
Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis (2009) 1.86
Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol (2011) 1.85
Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. Anal Chem (2006) 1.84
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol (2012) 1.82
Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res (2011) 1.82
Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. Eur Urol (2010) 1.79
Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits? J Urol (2010) 1.78
Prostate cancer: estimating the benefits of PSA screening. Nat Rev Urol (2009) 1.76
Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer (2006) 1.75
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst (2003) 1.73
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res (2009) 1.68
Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates. J Urol (2010) 1.66